Month: October 2025
Excerpt from the Press Release: TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ — HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of HCB101, an engineered SIRPα-Fc fusion protein, has been published in the Journal of Hematology & Oncology…
Read More
No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Excerpt from the Press Release: NEW YORK–(BUSINESS WIRE)– Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ — CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its proprietary DNA Aptamer therapy, CGB-600, for the treatment of vitiligo. The investigational active…
Read More
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Excerpt from the Press Release: FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis’ highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a useful tool in assessing the maintenance…
Read More
Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study…
Read More
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
Excerpt from the Press Release: BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.…
Read More
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing…
Read More
Excerpt from the Press Release: BOSTON and SOUTH SAN FRANCISCO, Calif. (October 14, 2025) – Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule, precision oncology and immunology drugs against previously undruggable disease-causing targets, today announced its latest development candidate. FMC-242 is a covalent allosteric inhibitor that breaks the interaction…
Read More
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor…
Read More
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the…
Read More